In 2010, the NHIF included in the list two new molecules: anti-IL-6-tocilizumab and anti-CD20-rituximab with indication RA (rituximab received approval also for Wegener’s disease in 2015). This evidence concerns the gene IL6 and rheumatoid arthritis.